心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Neurol Clin Pract：脑出血合并非瓣膜房颤的管理意见

2018-03-20 杨中华 脑血管病及重症文献导读

脑出血非瓣膜房颤抗凝管理
关注

2018年2月梅奥诊所的Maximiliano A.Hawkes等在Neurology Clinical Practice上发表了题为《脑出血后房颤的抗凝治疗》的系统性综述，现将他们关于脑出血合并非瓣膜房颤的推荐意见摘录如下。

2018年2月梅奥诊所的Maximiliano A.Hawkes等在Neurology Clinical Practice上发表了题为《脑出血后房颤的抗凝治疗》的系统性综述，现将他们关于脑出血合并非瓣膜房颤的推荐意见摘录如下，您同意他的观点吗？



图：脑出血合并非瓣膜房颤的推荐意见

备注：服用维生素拮抗剂（VKA）者应该严密监测INR。BP-血压，DOAC-直接口服抗凝剂，LAAO-左心耳封堵术，NOAC-新型口服抗凝剂，OAC-口服抗凝剂，SAH-蛛网膜下腔出血

原始出处：
Maximiliano A. Hawkes and Alejandro A. Rabinstein. Anticoagulation for atrial fibrillation after intracranial hemorrhage: A systematic review. Neurol Clin Pract.2018 Feb;8(1):48-57.doi:10.1212/CPJ.0000000000000425.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000367, encodeId=2fa7200036e4d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jan 07 16:13:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583556, encodeId=3734158355655, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Thu Mar 22 10:13:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298239, encodeId=98b0298239e1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Mar 21 07:15:59 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298220, encodeId=345f2982209e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 21 06:57:21 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298105, encodeId=2909298105e0, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 20 20:01:32 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
    2019-01-07 yinhl1978

    #Neurol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2000367, encodeId=2fa7200036e4d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jan 07 16:13:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583556, encodeId=3734158355655, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Thu Mar 22 10:13:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298239, encodeId=98b0298239e1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Mar 21 07:15:59 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298220, encodeId=345f2982209e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 21 06:57:21 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298105, encodeId=2909298105e0, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 20 20:01:32 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
    2018-03-22 12498e5fm17(暂无昵称)

    #瓣膜#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2000367, encodeId=2fa7200036e4d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jan 07 16:13:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583556, encodeId=3734158355655, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Thu Mar 22 10:13:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298239, encodeId=98b0298239e1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Mar 21 07:15:59 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298220, encodeId=345f2982209e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 21 06:57:21 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298105, encodeId=2909298105e0, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 20 20:01:32 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
    2018-03-21 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2000367, encodeId=2fa7200036e4d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jan 07 16:13:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583556, encodeId=3734158355655, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Thu Mar 22 10:13:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298239, encodeId=98b0298239e1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Mar 21 07:15:59 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298220, encodeId=345f2982209e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 21 06:57:21 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298105, encodeId=2909298105e0, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 20 20:01:32 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
    2018-03-21 yfjms

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2000367, encodeId=2fa7200036e4d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jan 07 16:13:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583556, encodeId=3734158355655, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Thu Mar 22 10:13:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298239, encodeId=98b0298239e1, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Mar 21 07:15:59 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298220, encodeId=345f2982209e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Wed Mar 21 06:57:21 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=298105, encodeId=2909298105e0, content=学习了.好文章., beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Mar 20 20:01:32 CST 2018, time=2018-03-20, status=1, ipAttribution=)]
    2018-03-20 1e0f8808m18(暂无匿称)

    学习了.好文章.

    0

相关资讯

Neurology：直接口服抗凝剂或华法林相关的脑出血比较！

由此可见，该研究结果显示DOAC治疗的患者较少发生严重的ICH和较低的死亡率，相比于有华法林治疗的患者，可能是由于入院时轻微出血和血肿扩大的频率较低所致。

Stroke：儿童身高和生长与首次缺血性卒中或脑出血有关！

由此可见，了解错过卒中预防机会的预测性病人特征，可能有助于初级保健识别和妥善管理这些个体。改善这些群体的管理可以减少他们的风险，并且可以预防未来大量的卒中和TIA患者。

Neurosurgery：脑出血后早期预防VTE现状调查

深静脉血栓形成（DVT）和肺栓塞（PE）是脑出血患者致死和致残的主要原因。脑出血患者的静脉血栓栓塞（VTE）是缺血性卒中的四倍。脑出血后症状性VTE发生率为1-10%，无症状性VTE为20-80%。

Neurology：脑出血周围水肿峰值与功能预后相关！

由此可见，峰值PHE体积是ICH后功能预后的独立预测因子。炎症过程和血肿扩张似乎与PHE的演变有关，可能是重要的治疗靶点。

Stroke：脑出血致脑卒中随机对照试验的特点！

在随机对照试验（RCTs）中，脑出血治疗获得的好处仍然存在欠缺，这可能是由于缺乏治疗效果或设计的RCTs。近期，一项发表在杂志Stroke上的研究在2015年12月搜索了Cochrane中风组试验注册，以了解已完成并发表的RCT报告了脑出血患者的临床结局。研究者们收集了出版年份和语言，研究特征和效应量的数据。如果研究进行了≥2的描述随机化，使用盲法或指定主要结果，则认为随机对照试验的风险较低。此项

SCI REP：血浆同型半胱氨酸浓度与脑出血风险！

总之，Hcy水平可能是动脉粥样硬化的加重因素，与ICH的高风险呈正相关。亚洲人和白种人的种族差异对ICH的风险没有影响。